Comparing the current results to its competitors, Seastar Medical Holding reported Revenue increase in the 2 quarter 2026 by 81.95 % year on year. The sales growth was above Seastar Medical Holding's competitors' average revenue growth of 8.22 %, achieved in the same quarter.
Seastar Medical Holding's Comment on Competition and Industry Peers
Following FDA HDE approval for pediatric patients with AKI in February 2024, the company employs a direct sales and marketing model for QUELIMMUNE. They terminated a third-party distribution agreement to support this approach and have hired internal sales and marketing staff to expand their presence in the U.S. pediatric market. Limited third-party coverage and reimbursement may affect adoption and competitive positioning.
Due to outstanding performance in Overall company, revenue grew by 81.95 % Seastar Medical Holding Corp improved its market share, to approximately 0.53 %.
July 26, 2024
Shareholder Alert: Class Action Lawsuit Filed Against SeaStar Medical Holding Corporation for Alleged Securities Law Violations In a significant legal development, Pomerantz LLP has announced the filing of a class action lawsuit against SeaStar Medical Holding Corporation (NASDAQ: ICU) and specific officers. This lawsuit, initiated in the United States District Court for the District of Colorado under the case number 24-cv-01873, aims to address alleged violations of federal securities laws by the company.According to the details outlined in the lawsuit, the Class Period in question spans from October 31, 2022, to March 26, 2024. The class action is on behalf of all individuals and entities, excluding the de...
Publicly Traded Peers of Seastar Medical Holding Corp
Aquabounty Technologies Inc Share Performance
-17.03%
30 Days
Aquabounty Technologies Inc
Profile
Aquabounty Technologies Inc's business model revolves around the development and commercialization of genetically engineered fish, particularly the AquAdvantage salmon. They aim to produce and sell these fast-growing, bioengineered salmon to meet the global demand for seafood, while also maintaining a focus on sustainability and improving efficiency in aquaculture.
Xperi Inc operates based on a licensing and technology business model. The company develops and acquires intellectual property in areas such as audio, imaging, and semiconductor technologies, and licenses these innovations to a wide range of customers across various industries. Through its licensing agreements, Xperi Inc generates revenue streams by granting others the right to use its patented technologies and intellectual property.
Sources:
Seastar Medical Holding Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Seastar Medical Holding Corp versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
